The identification of cell proliferation, migration and immune-response pathways as key prognostic determinants in HER2+:ERα- breast cancer suggests that IHC assays that can faithfully detect alterations in these pathways may be highly prognostic. The gene discussed is ESR1; the disease is breast carcinoma.